In this exclusive Life Science Leader podcast, Chris Conway, manager of business development at AMRI (a pharmaceutical CRO [contract research organization]) discusses critical outsourcing decision points, the trend toward overseas outsourcing, and the differences between biotechs and big pharma in...

Today, more biotechs are looking at acquisition as their primary exit strategy. Toban Zolman, director of consulting services at life sciences consulting/software firm ISI, discusses some criteria biotechs will be evaluated on and how these companies can prepare for acquisition.

Counterfeit pharmaceuticals continue to be a worldwide problem and there are varying ways pharma companies are fighting back. While there is no one perfect solution, Life Science Leader editor Dan Schell discusses one option with Ahura Scientific's Duane Sword.

Mark Collins, marketing director of the cellular imaging and analysis group at Thermo Fisher Scientific, expresses his opinion on the key concerns of the pharma and biotech industries right now. He also discusses why cellular imaging is such a powerful tool for in vitro toxicity testing.

In this interview with Patheon CEO Wes Wheeler, he explains why the CDMO (contract development and manufacturing organization) has added a new performance guarantee. Wheeler also discusses how this guarantee is measured and how the company's new Lean Six Sigma initiative is contributing to the...